Tag Archives: patents

Here are the Facts about the IPR Kill Rate


FiercePhrma recently ran an article repeating a dubious analysis of the crisis caused by the rapidly increasing number of biopharma related inter partes reviews (IPR) currently within the United States Patent and Trademark Office (PTO). It is troubling that in a single breath Ronny Gal both dismissed the biopharmaceutical industry’s concerns with the PTO’s IPR process and acknowledged that limited data prevents any firm conclusions about the potential impact of IPR on biotech innovation. If Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , ,

102 Organizations Urge Congress to Maintain a Strong Patent System and Protect Innovation

US Capitol Building

A diverse group of more than 100 national and state-based advocacy organizations have united to urge Congress to preserve important patent protections that incentivize biopharmaceutical research necessary to innovate and develop new cures and treatments for serious diseases. In a letter sent to the Hill this week, these patient advocates asked Congress to amend the Innovation Act (H.R. 9) to preserve the highly-detailed and sophisticated systems designed by Hatch-Waxman and BPCIA and avoid weakening the Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , ,

CNBC Commentary: Hedge funds, ‘reverse trolls’ crushing biopharma innovation

Vote No on HR 9

Patents are the lifeblood of medical innovation. They are the cornerstone that enables companies to perform the long and costly research and development for cures and therapies to combat devastating diseases such as cancer, HIV and Alzheimer’s. Unfortunately, the system that helps protect these innovations is being abused by outside interests. BIO and others have called upon Congress to fix these problems as part of a greater patent reform debate. Today one more voice joined Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , ,

2015 BIO World Congress Will Hold Workshops Focusing on Current Investment Trends

BIO World Congress

BIO recently announced the schedule of workshops for the 2015 World Congress on Industrial Biotechnology. These workshops are designed for focused discussions on the newest trends in business strategies, investment opportunities and technology development in industrial biotechnology. Brent Erickson, executive vice president for BIO’s Industrial & Environmental Section argued that: “Government policies supporting the development of biomass and biobased products signals to private investors that there is a strong market for these products. The confluence of policy and Read More >

Biofuels & Climate Change  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

IP Sessions at BIO 2015: The Impact of the Inter Partes Review on (BIO)Pharma


The Intellectual Property Track at the BIO International Convention was a chance for IP thought leaders in the biotech sector to discuss some of the most pressing issues impacting the industry. Let’s recap what we learned from one of the IP sessions at BIO 2015: The Impact of IPRs on (BIO)Pharma On Tuesday, patent litigation experts met to discuss inter partes review proceedings and how they are impacting biotechnology. Panelists from The Impact of IPRs Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , , , , , , , ,